[(8R,9S,13S,14S,17S)-3-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl] 3-cyclopentylpropanoate;4-[(3S,4R)-4-(4-hydroxyphenyl)hexan-3-yl]phenol

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: [(8R,9S,13S,14S,17S)-3-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl] 3-cyclopentylpropanoate;4-[(3S,4R)-4-(4-hydroxyphenyl)hexan-3-yl]phenol
• 化学式: C44H58O5
• 分子量: 666.9
• InChiKey: PFALFISSGXENSM-KVUSMLIRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  10.92
• 重原子数：
  49
• 可旋转键数：
  10
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  87
• 氢给体数：
  3
• 氢受体数：
  5

文献信息

• SELF-ASSEMBLY OF THERAPEUTIC AGENT-PEPTIDE NANOSTRUCTURES
  申请人：Ohio State Innovation Foundation

  公开号：US20140155577A1

  公开（公告）日：2014-06-05

  Disclosed are conjugates of hydrophobic drugs linked to protected or unprotected amino acids or peptides. The disclosed conjugates are amphiphilic and can self assemble into nanotubes. Nanotubes comprising the conjugates are also described and can have high loading of the drug and protect it from degradation or elimination. The nanotubes are well suited to deliver hydrophobic and unstable drugs to individuals.

  揭示了与受保护或未受保护的氨基酸或肽连接的疏水药物的共轭物。所述的共轭物是两性的，可以自组装成纳米管。还描述了包含这些共轭物的纳米管，可以具有高药物载荷并保护药物免受降解或排泄。这些纳米管非常适合向个体输送疏水和不稳定的药物。
• Self-assembly of therapeutic agent-peptide nanostructures
  申请人：Ohio State Innovation Foundation

  公开号：US10098967B2

  公开（公告）日：2018-10-16

  Disclosed are conjugates of hydrophobic drugs linked to protected or unprotected amino acids or peptides. The disclosed conjugates are amphiphilic and can self assemble into nantubes. Nanotubes comprising the conjugates are also described and can have high loading of the drug and protect it from degradation or elimination. The nanotubes are well suited to deliver hydrophobic and unstable drugs to individuals.

  所公开的是疏水性药物与受保护或未受保护的氨基酸或肽连接的共轭物。所公开的共轭物具有两亲性，可自行组装成纳米管。此外，还描述了包含共轭物的纳米管，这种纳米管可具有较高的药物负载量，并能保护药物不被降解或消除。纳米管非常适合向人体输送疏水性和不稳定的药物。
• PREPARATIONS OF HYDROPHOBIC THERAPEUTIC AGENTS, METHODS OF MANUFACTURE AND USE THEREOF
  申请人：Aciex Therapeutics, Inc.

  公开号：EP2847207A1

  公开（公告）日：2015-03-18
• THERMOGENIC COMPOSITIONS AND METHODS
  申请人：Ohio State Innovation Foundation

  公开号：US20190083574A1

  公开（公告）日：2019-03-21

  Thermogenic molecules and methods of using these molecules for treating or preventing a condition in a subject selected from the group consisting of visceral fat accumulation (e.g., Crohn's disease associated with visceral fat accumulation), obesity, diabetes, pre-diabetes, hypothermia, and chronic inflammation are disclosed. Also disclosed is a method for promoting glucose uptake in peripheral tissues (e.g., adipocytes and muscles) of a subject, enhancing nerve innervation in a subject, activating PI3 kinase in cell, and inducing leptin secretion by an adipocyte. Also disclosed are inhibitors of thermogenic molecules and methods of using these inhibitors to decrease thermogenesis of adipocytes in a subject. Also disclosed are self-assembled, biocompatible nanostructure non-covalently associated with a therapeutic or diagnostic peptide or peptidomimetic.
• [EN] PREPARATIONS OF HYDROPHOBIC THERAPEUTIC AGENTS, METHODS OF MANUFACTURE AND USE THEREOF<br/>[FR] PRÉPARATIONS D'AGENTS THÉRAPEUTIQUES HYDROPHOBES, PROCÉDÉS DE FABRICATION ET UTILISATION DE CEUX-CI
  申请人：ACIEX THERAPEUTICS INC

  公开号：WO2013169647A1

  公开（公告）日：2013-11-14

  The present invention further provides method of preparing nanocrystals of a hydrophobic therapeutic agent such as fluticasone or triamcinolone, pharmaceutical compositions (e.g., topical or intranasal compositions) thereof and methods for treating and/or preventing the signs and/or symptoms of disorders such as blepharitis, meibomian gland dysfunction or skin inflammation or a respiratory disease (e.g., asthma).